Company Cellectar Biosciences Inc Nasdaq

US15117F2039

Pharmaceuticals

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Other Pharmaceuticals

Inactive Instrument

End-of-day quote Nasdaq Other stock markets
- ^USD	-

14/05	Transcript : Cellectar Biosciences, Inc., Q1 2024 Earnings Call, May 14, 2024
14/05	Cellectar Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. Its Iopofosine is evaluated in the completed CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstromâs macroglobulinemia (WM).

Managers	Title	Age	Since
James Caruso CEO	Chief Executive Officer	65	15/15/15
Chad Kolean DFI	Director of Finance/CFO	59	28/14/28
Andrei Shustov CTO	Chief Tech/Sci/R&D Officer	-	15/23/15
Jarrod Longcor COO	Chief Operating Officer	51	15/16/15
Shane Lea PRN	Corporate Officer/Principal	-	21/22/21

Members of the board	Title	Age	Since
Fred Driscoll BRD	Director/Board Member	74	07/17/07
Douglas Swirsky CHM	Chairman	54	07/17/07
John Neis BRD	Director/Board Member	68	01/08/01
James Caruso CEO	Chief Executive Officer	65	15/15/15
Stefan Loren BRD	Director/Board Member	60	15/15/15
Asher Chanan-Khan BRD	Director/Board Member	55	24/21/24

	Vote	Quantity	Free-Float	Total Float
Stock A	0	238	0	90.91 %
Stock B	0	111	0
Stock C	0	1,237	0
Stock D	1	35,848,924	32,591,316 ( 90.91 %)

Name	Equities	%	Valuation
Rosalind Advisors, Inc. 9.222 %	3,305,936	9.222 %	10 M $
AIGH Capital Management LLC 7.824 %	2,804,917	7.824 %	8 M $
AIGH Capital Management LLC 7.427 %	2,662,324	7.427 %	8 M $
Nantahala Capital Management LLC 5.226 %	1,873,325	5.226 %	6 M $
Adar1 Capital Management LLC 5.088 %	1,824,063	5.088 %	6 M $
Vanguard Global Advisers LLC 3.323 %	1,191,081	3.323 %	4 M $
Laurence Lytton 2.504 %	897,605	2.504 %	3 M $
Adar1 Capital Management LLC 1.792 %	642,541	1.792 %	2 M $
Rosalind Advisors, Inc. 1.734 %	621,478	1.734 %	2 M $
Barclays Capital, Inc. 0.9434 %	338,198	0.9434 %	1 M $

Name	Equities	%	Valuation
Skaana Management LP -	0	-	- $

Cellectar Biosciences, Inc.

100 Campus Drive

07932, Florham Park

+608 441 8120

http://www.cellectar.com

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+32.09%	69TCr
NOVO NORDISK A/S	+29.39%	58TCr
JOHNSON & JOHNSON	-1.34%	37TCr
MERCK & CO., INC.	+20.34%	33TCr
ABBVIE INC.	+7.39%	29TCr
ASTRAZENECA PLC	+14.25%	24TCr
ROCHE HOLDING AG	-3.03%	21TCr
NOVARTIS AG	+10.02%	21TCr
AMGEN INC.	+8.49%	17TCr

Other Pharmaceuticals